Peptides for Weight Loss: What Actually Works

Weight loss became the largest peptide story in medicine after the STEP 1 trial (Wilding et al., NEJM 2021) showed semaglutide 2.4 mg dropping a mean 14.9% body weight over 68 weeks in non-diabetic adults. The placebo arm dropped 2.4%. The 12.5-point gap was the largest non-surgical weight-loss effect any pharmaceutical had ever produced.

Three years later, SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed tirzepatide (dual GLP-1/GIP) producing 20.9% mean weight loss at 72 weeks. Retatrutide's Phase 2 trial (Jastreboff et al., NEJM 2023) hit 24.2% at 48 weeks with a triple agonist hitting GLP-1, GIP, and glucagon receptors. The trajectory is clear: each new generation pushes effect size higher.

But trial means hide individual variance. The same 2.4 mg of semaglutide produces a 25% drop in one person and a 4% drop in another. That gap is not motivation. GLP1R receptor genotype, baseline insulin resistance, and gut peptide signaling each account for measurable variance. The TRIM trial (Phenomix Sciences, Cell Metabolism 2023) was the first to demonstrate this directly — patients carrying favorable GLP1R variants lost meaningfully more weight on the same dose.

GLP-1 receptor agonists work because they hit a real biological lever: the hypothalamic satiety signal. The molecule slows gastric emptying (you feel full longer), amplifies the post-prandial GLP-1 spike (insulin release is more efficient), and binds GLP-1 receptors in the brainstem and arcuate nucleus (food noise quiets down). Most users report appetite suppression within 48 hours of the first dose.

The newer dual and triple agonists add more levers without losing the original mechanism. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) — which modulates fat metabolism and insulin sensitivity through a different receptor pathway. Retatrutide adds glucagon receptor activity on top, which raises basal energy expenditure by an estimated 100-150 kcal/day in the dosing range studied.

The non-prescription options are weaker. AOD-9604 (a 16-amino-acid fragment of growth hormone) targets fat metabolism specifically but its Phase IIb trial in 536 obese adults failed the primary endpoint — mean weight loss at 12 weeks was 2.6 kg vs. 0.8 kg placebo, statistically significant but clinically unimpressive next to the GLP-1 numbers. The compound continues to be used in body-recomposition protocols but it should not be your primary tool if weight loss is the goal.

The pharmacogenomic literature on GLP-1 receptor agonists is the strongest in any peptide class. Five SNPs explain most of the response variance:

• GLP1R rs10305420 — the headline variant. T-allele carriers in the Phenomix Sciences TRIM trial lost nearly twice as much body weight as C-allele carriers on identical semaglutide protocols. This is the single best-validated peptide pharmacogenomic finding.
• GLP1R rs6923761 (Gly168Ser) — affects receptor desensitization rate. Serine carriers show stronger and more sustained response, with less tachyphylaxis at higher doses.
• TCF7L2 rs7903146 — affects pancreatic beta-cell function and insulin secretion. The T allele predicts faster glucose response to semaglutide but also higher type 2 diabetes risk; net effect on weight loss is positive.
• FTO rs9939609 — the "obesity gene." A-allele carriers respond particularly well to GLP-1 + high-protein dietary pattern; the variant alters hypothalamic ghrelin signaling.
• MC4R variants — melanocortin-4 receptor mutations affect satiety signaling. Carriers of activating variants respond strongly to GLP-1 satiety signal. Rare loss-of-function variants predict reduced response.

A pharmacogenomic report does not change whether semaglutide will work — for most people it will, to some degree. What it changes is the expected magnitude. If your DNA puts you in the high-response cluster, the expected value of going through the prescription, injections, and GI side effects is meaningfully higher than the trial mean suggests. If your DNA puts you in the low-response cluster, your time is better spent on a different approach.

STEP 1 (Wilding et al., NEJM 2021). 1,961 non-diabetic adults with BMI ≥30. Semaglutide 2.4 mg weekly vs. placebo over 68 weeks. Mean weight loss 14.9% vs. 2.4%. 86.4% of semaglutide arm achieved ≥5% loss. Discontinuation rate 7% (GI side effects).

STEP 5 (Garvey et al., Nature Medicine 2022). Two-year extension. Mean weight loss sustained at 15.2% through 104 weeks. The trajectory plateaus around week 60-68 in most patients; the second year is mostly maintenance.

SURMOUNT-1 (Jastreboff et al., NEJM 2022). 2,539 adults with obesity. Tirzepatide 5/10/15 mg vs. placebo. Mean weight loss at 72 weeks: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) vs. 3.1% placebo. 91% of high-dose arm achieved ≥5% loss.

TRIUMPH (retatrutide Phase 2, Jastreboff et al., NEJM 2023). 338 adults with obesity, 48 weeks. Mean weight loss 17.5% (8 mg) and 24.2% (12 mg) vs. 2.1% placebo. Phase 3 ongoing. Side effect profile similar to tirzepatide — primarily GI, declining after dose stabilization.

Phenomix Sciences / TRIM (Camilleri et al., Cell Metabolism 2023). First trial to demonstrate pharmacogenomic stratification of GLP-1 response. Carriers of the predicted-responder GLP1R variant lost a mean 19.2% body weight on semaglutide; non-carriers lost 10.0%. Same dose, same protocol, almost double the effect.

If insurance covers semaglutide: start there. Largest evidence base, most prescribers comfortable with it, longest real-world dataset. Plan for 12-18 months on protocol.

If insurance covers tirzepatide but not semaglutide: tirzepatide is the better choice — larger effect size in head-to-head trials, similar side effect profile. The SURMOUNT-5 trial directly compared the two and tirzepatide won on weight loss at every dose tier.

If paying out of pocket and budget is tight: compounded semaglutide from a licensed compounding pharmacy (not a research-chemical supplier) is significantly cheaper. Ask your prescriber for a referral to a licensed compounder; verify with the state pharmacy board.

If your priority is muscle preservation and body composition over scale weight: CJC-1295 + ipamorelin stack alongside resistance training, with optional AOD-9604 layered in. This is the body-recomposition approach — slower weight loss but better lean-mass retention. See the fat-loss guide for details.

If you have type 2 diabetes: semaglutide and tirzepatide both have FDA approval for diabetes management at lower doses. The weight-loss effect comes free with diabetes treatment. Start there before considering off-label dosing.

If you carry the GLP1R favorable variant: the expected value of any GLP-1 protocol is substantially higher for you than for the population mean. Go aggressive on the titration tolerability allows. You are likely to land in the top quartile of responders.

If you have a history of gallbladder disease, pancreatitis, or medullary thyroid carcinoma: GLP-1 receptor agonists are contraindicated or require careful supervision. AOD-9604 and CJC-1295 do not carry the same risks but produce much smaller effects. Discuss alternatives with your physician.

Standard semaglutide escalation. 0.25 mg weekly subcutaneous for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then 2.4 mg ongoing. Total escalation 16 weeks. Faster titration causes severe nausea in 40%+ of patients and accounts for most discontinuations. Slower titration is fine and may improve tolerability.

Standard tirzepatide escalation. 2.5 mg weekly for 4 weeks, then 5 mg, then 7.5, 10, 12.5, 15 mg in 4-week increments. Most users find 10-12.5 mg the sweet spot for weight loss with manageable side effects. 15 mg adds modest weight loss but doubles GI complaint rate.

Injection technique. Subcutaneous, abdomen or thigh, rotate sites weekly. Same day each week (most users do Sunday evening). The drug has a long half-life (semaglutide: ~7 days; tirzepatide: ~5 days), so an exact same time each week is not critical, but the same day improves adherence.

Stacking. GLP-2 (gut barrier peptide) is sometimes added to manage GI side effects from GLP-1 dosing. BPC-157 supports gut healing if nausea persists. Some practitioners cycle in CJC-1295 + ipamorelin during weight-loss plateaus to preserve muscle mass. Do not combine GLP-1 with AOD-9604 same-day — both target metabolism through overlapping pathways.

Protein and resistance training are non-negotiable. Without 1.6-2.2 g/kg/day protein and 3+ resistance sessions per week, expect 25-35% of your weight loss to come from lean tissue. The visible result will be smaller-but-flabby rather than smaller-and-fitter. Worse, the lower lean mass tanks basal metabolic rate, which is why most semaglutide patients regain quickly after stopping.

Week 1-2. Appetite suppression begins within 48 hours of first injection. "Food noise" decreases noticeably. Mild nausea common, especially in first 24 hours after each dose. Weight loss 0.5-1.5 kg in week 1, mostly water and gut content.

Week 3-8. Steady weight loss, typically 0.5-1.0 kg per week. Nausea declines after each dose-escalation step but returns briefly with each titration. Most users hit 5% body weight loss by week 8 — the FDA-recognized clinically meaningful threshold.

Week 9-20. Continued steady loss. Most users reach 10% body weight loss by week 16-20. GI side effects stabilize around the 2.4 mg dose (semaglutide) or 10 mg (tirzepatide). This is the phase where resistance training becomes critical — muscle preservation pays back over years.

Week 21-52. Loss rate slows. Most users reach 12-17% by week 52 on semaglutide, 18-21% on tirzepatide. Plateau periods of 4-8 weeks are normal. Body composition continues to improve even when scale stalls.

Week 52-68. Plateau dominates. Final 1-3% loss happens slowly. STEP 1 showed the curve flattening around week 60. After this, you are maintaining the new set point, not losing.

Post-discontinuation. The 2-year STEP 4 follow-up showed mean regain of 11.6 kg over 68 weeks after stopping semaglutide. Patients regained roughly two-thirds of what they lost. This is why the current standard-of-care framing has shifted toward indefinite low-dose use rather than time-limited courses.

Skipping the protein requirement. The single biggest mistake. Patients who don't hit 1.6 g/kg body weight in protein lose substantial muscle mass alongside fat. The visible result is the "Ozempic face" — gaunt, deflated — and a metabolism that is now 200-400 kcal/day lower than before, guaranteeing fast regain. Track grams of protein daily for the first 12 weeks until it is automatic.

Stopping at 5% loss because it “feels enough.” The trial data shows the curve still climbs through week 52. Stopping early locks you out of the cumulative effect and starts the regain clock. If you stop at month 4 having lost 10%, you will likely regain 6-7% within 12 months. If you ride it through month 12 and reach 17%, post-discontinuation regain is the same in absolute terms but you are still net-down meaningfully.

Escalating too fast. Bumping from 0.25 to 1.0 mg in two weeks because "I'm not feeling it" causes severe nausea and triggers the discontinuation cascade. The 16-week semaglutide titration exists for a reason. Stick to it.

Buying compounded peptides from research-chemical sources. The FDA issued enforcement letters against several compounding pharmacies in 2024. Identity testing on samples from research-chemical suppliers has shown active ingredient variance ranging from 60% to 130% of stated dose, plus contaminants. The price difference is not worth the dosing chaos. Get a real prescription through a telehealth service.

Stacking with stimulants. Some users add bupropion, phentermine, or stimulant pre-workouts during the early weight-loss phase. The combination raises heart rate and blood pressure into ranges that have triggered cardiovascular events in case reports. Do not combine GLP-1 with sympathomimetic stimulants without explicit physician supervision.

Ignoring the gut healing window. GLP-1 slows gastric emptying. Existing gut issues (reflux, gastroparesis, IBS-C) get worse before they get better. Address gut health proactively in the first 4 weeks — fiber, hydration, sometimes BPC-157 — rather than waiting for symptoms.

Most common side effects (>10% of users). Nausea, vomiting, diarrhea, constipation, abdominal pain. All gut-related. Most resolve within 4-8 weeks. Severity tracks with titration speed — slower escalation = milder symptoms.

Less common but important. Gallbladder events (cholelithiasis, cholecystitis) — about 1.5% incidence in STEP trials, vs. 0.4% placebo. Rapid weight loss is the underlying driver. Acute pancreatitis is a known signal — about 0.3% in trials, but enough that any persistent upper-abdominal pain requires evaluation.

Cardiovascular signal is positive. SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide reduced MACE (major adverse cardiovascular events) by 20% in patients with existing cardiovascular disease. This is one of the few weight-loss interventions with a documented cardio benefit.

Thyroid C-cell tumor warning (boxed). Based on rat studies. Human relevance unclear, but contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Check thyroid history before starting.

Hypoglycemia. Rare in non-diabetics. More common when stacking with sulfonylureas or insulin. Not typically a concern in lean-population off-label use.

Pregnancy. Contraindicated. Discontinue 2 months before planned pregnancy. The drug's long half-life means it takes 5-7 weeks to fully clear.

Monitoring. Baseline CBC, CMP, HbA1c, lipid panel. Repeat at 3 months. Symptom-driven evaluation otherwise. No routine imaging required.